I feel I should explain where I went wrong. Although I do not believe this explanation excuses the mistakes I made, you do speculate about my motivations, so I think it fair to respond to that. When I published the NAN argument -- which you rightly critique -- I did not, as you suggest, believe I suffered cognitive impairment or lasting psychosis from DXM use. I do appreciate that you dismissed the possibility of fraud; it has always been important to me to provide accurate and balanced information. I failed to do so, in this case, and am quite ashamed of that.
Four unrelated events occurred in the six months prior to publishing the NAN warning. First, I received an influx of reports of lasting cognitive impairment from DXM users (in retrospect, of course, I realize they were not sufficient for the conclusions I drew). Second, I was contacted by several very vocal critics of the DXM FAQ, two of whom were angry enough to make threats. Third, I discovered that adolescents were making extensive use of DXM and misunderstanding, if not dismissing outright, some of the more measured warnings in the FAQ. In response I made the classic drug war blunder: if they aren't listening, try scaring them. Fourth, and perhaps most influential, I was experiencing a hypomanic episode and did not recognize either it or the mistakes I was making (I do not know whether DXM triggered the episode itself, though when I was diagnosed as bipolar, I had long ceased DXM use and history prior to DXM use was considered relevant).
Even at the time I expected a critique or rebuttal from the community; the only one I recall receiving was to the claim that nitrous oxide was an NMDA antagonist. I found this quite surprising. I should have submitted the paper to others for review prior to publication online, just as I did with the FAQ itself.